Careers in Israel
Careers in USA
Board of Directors
Scientific Advisory Board
Johns Hopkins University
Mount Sinai Hospital
Annual and Quarterly Reports
Therapeutic product discovery
In the information age
The next wave in immuno-oncology
Jan 22, 2019
Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy
Jan 14, 2019
Compugen’s Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium
Our optimized process for predictive discovery of novel drug targets
Discovery & development of first-in-class monoclonal antibody therapeutics
Compugen, FROM CODE TO CURE
CGEN-15029 is the internal designation for PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by...
CGEN-15137 is the internal designation for TIGIT, an immune checkpoint in the B7/CD28 family which has recently gained broad...
CGEN-15001T is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15001T is expressed in various subpopulations of immune cells...
CGEN-15001 is our lead program for autoimmune diseases. It is a first-in-class therapeutic candidate of a novel inhibitory checkpoint pathway, with the potential to restore...
Feb 28, 2019
COM701 Phase 1 Study Trial-in-Progress Poster Presentation, The ASCO-SITC Clinical Immuno-Oncology Symposium
San Francisco, CA
Nov 07, 2018
Compugen Third Quarter 2018 Conference Call
Oct 11, 2018
Bristol-Myers Squibb Clinical Collaboration and Equity Investment Conference Call
Click here for more info about partnering with Compugen